TAK-573, an anti-CD38-targeted attenuated interferon alpha (IFNα) fusion protein, showed anti-myeloma tumor responses in combination with standard of care (SOC) agents in multiple myeloma (MM) xenograft tumor models in vivo

Autor:	Fatholahi, Marjan 1, Valencia, Miriam 1, Mark, Armanini 1, Bi, Mingying 1, Syed, Sakeena 2, Zhang, Yuhong 2, Taura, Tetsuya 1, Yun, Yong 1, Wilson, David 1, Chattopadhyay, Nibedita 2, Bjorck, Pia 1, Curley, Michael 2, Sarah, Pogue 1
Zdroj:	In Clinical Lymphoma, Myeloma and Leukemia October 2019 19(10) Supplement:e116-e116
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect